Spark Therapeutics priced its initial public offering at $23 per share and the company's stock closed its first day of trading up 117.4% at $50, showing that investors are willing to place big bets on gene therapy that could cure or substantially reduce treatment burdens for severe diseases and conditions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?